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Summary
Background Rwanda has achieved substantial progress in scaling up of antiretroviral therapy. We aimed to assess the 
eﬀ ect of increased access to antiretroviral therapy on life expectancy among HIV-positive patients in two distinct 
periods of lower and higher antiretroviral therapy coverage (1997–2007 and 2008–11).
Methods In a retrospective observational cohort study, we collected clinical and demographic data for all HIV-positive 
patients enrolled in care at 110 health facilities across all ﬁ ve provinces of Rwanda. We included patients aged 15 years 
or older with a known enrolment date between 1997 and 2014. We constructed abridged life tables from age-speciﬁ c 
mortality rates and life expectancy stratiﬁ ed by sex, CD4 cell count, and WHO disease stage at enrolment in care and 
initiation of antiretroviral therapy.
Findings We included 72 061 patients in this study, contributing 213 983 person-years of follow-up. The crude mortality 
rate was 33·4 deaths per 1000 person-years (95% CI 32·7–34·2). Life expectancy for the overall cohort was 
25·6 additional years (95% CI 25·1–26·1) at 20 years of age and 23·3 additional years (95% CI 22·9–23·7) at 35 years 
of age. Life expectancy at 20 years of age in the period of 1997–2007 was 20·4 additional years (95% CI 19·5–21·3); for 
the period of 2008–11, life expectancy had increased to 25·6 additional years (95% CI 24·8–26·4). Individuals 
enrolling in care with CD4 cell counts of 500 cells per μL or more, and with WHO disease stage I, had the highest life 
expectancies.
Interpretation This study adds to the growing body of evidence showing the beneﬁ t to HIV-positive patients of early 
enrolment in care and initiation of antiretroviral therapy.
Funding Bill & Melinda Gates Foundation.
Copyright © Nsanzimana et al. Open Access article distributed under the terms of CC BY-NC-SA.
Introduction
Before the global scale-up of antiretroviral therapy, data 
from many regions of the world consistently showed a 
strong negative association between adult HIV 
prevalence and life expectancy.1 Because access to 
antiretroviral therapy has greatly improved in many 
regions of the world, this negative association is 
dwindling. Reductions in morbidity and mortality 
associated with antiretroviral therapy have translated into 
increased life expectancy and decreased years of life 
lost.2,3 A collaborative cohort analysis by the Antiretroviral 
Therapy Cohort Collaboration2 showed that patients in 
Europe and North America who started antiretroviral 
therapy at age 20 years between 2003 and 2005 could 
expect to live an additional 49 years after initiation of 
antiretroviral therapy, an overall increase in life 
expectancy of 81% since 1996. Findings from a similar 
analysis of data from Uganda showed that a 20-year-old 
individual starting antiretroviral therapy was projected 
an additional 26 years, increasing according to CD4 
status at antiretroviral therapy initiation.3
Rwanda has recently made remarkable progress in 
expansion of access to antiretroviral therapy.4 The country 
was recently singled out by the UN as one of the few to 
have achieved near-universal access to treatment in 2012, 
according to previous eligibility criteria for antiretroviral 
therapy (ie, 350 CD4 cells per μL or less).5 Rwanda ﬁ rst 
achieved universal coverage in 2008, with 80% of HIV-
positive patients receiving antiretroviral therapy under a 
CD4 eligibility criterion of 200 cells per μL or less, and 
then again in 2010, a year after the guidelines changed 
the eligibility criteria to 350 cells per μL or less. The 
government is now working to implement a new strategy 
to both raise the CD4 threshold for antiretroviral therapy 
initiation to 500 cells per μL or less and provide 
immediate antiretroviral therapy for key populations, 
including pregnant women through option B+ (in which 
all pregnant and breastfeeding women are eligible for 
lifelong antiretroviral therapy irrespective of CD4 cell 
count), HIV-positive patients with comorbidities, men 
who have sex with men, and female sex workers.6,7
This achievement makes the investigation of the eﬀ ect 
of HIV treatment scale-up on life expectancy among 
HIV-positive patients in Rwanda particularly interesting. 
Two distinct periods of antiretroviral therapy 
coverage can be retrospectively assessed: lower coverage 
(1997–2007), and higher coverage (2008 onwards). In an 
observational cohort study we aimed to evaluate life 
expectancy of HIV-positive people in Rwanda, ﬁ rst by 
constructing life tables among HIV-positive Rwandans 
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enrolled in care, and second by comparing these results 
across the two periods of lower and higher coverage of 
anti retroviral therapy.
Methods
Study design and participants
In an observational cohort study, we used data from the 
Rwanda Biomedical Center, which oversees surveillance 
of HIV/AIDS and scale-up of antiretroviral therapy 
within the country. The national treatment programme 
in Rwanda consists of monthly follow-up visits with 
health-care professionals for treatment pickup, CD4 
measurements every 6 months, and annual viral load 
monitoring, beginning 1 year after antiretroviral therapy 
initiation. This study used data from the IQ Charts 
database, an electronic medical record system that 
captures demographic and clinical characteristics at 
enrolment and longitudinal HIV-speciﬁ c clinical factors 
and vital statistics. This database began collecting data 
prospectively in 2004 and includes data obtained 
retrospectively for 1997–2003. The IQ Charts database 
covers 110 health facilities across all ﬁ ve provinces of 
Rwanda, providing a nationally representative sample of 
25% of facilities providing antiretroviral therapy over the 
study period.
For this study, we included all patients within these 
110 health facilities aged 15 years or older with a known 
enrolment date, follow-up time (ie, did not enter and exit 
the programme on the same day), and who enrolled in 
care between 1997 and 2011. We deﬁ ned enrolment in 
care as a patient having received a positive test result and 
subsequently registered for the ﬁ rst time in the 
monitoring and surveillance database. At enrolment a 
patient could be retained in the pre-antiretroviral therapy 
phase or begin antiretroviral therapy if clinically 
indicated. The IQ Charts database includes 
87 613 patients. As of 2013, roughly 176 000 Rwandans 
were retained in the national HIV care programme. 
Selection within this database is based on health facility 
rather than individuals. Large health facilities and rural 
health facilities have slightly higher probabilities of 
inclusion, but how this factor aﬀ ects patient 
characteristics is unknown.
The routinely collected programme data analysed for 
this study are maintained by the Rwanda Biomedical 
Centre, Division of HIV/AIDS, STIs and Other Blood 
Borne Infections; the ethical procedures for the collection 
of these data are governed by the Medical Research 
Council of Rwanda. Secondary analyses of routinely 
collected data are exempt from ethics approval when led 
by the Rwanda Biomedical Centre.
Procedures
We measured follow-up time in two ways: ﬁ rst, as time 
from enrolment into care to study exit due to end of study 
period, death, loss to follow-up, or transfer out to facilities 
not participating in IQ chart surveillance; and second, as 
time from antiretroviral therapy initiation to study exit. 
Mortality data were ascertained in health facilities and 
through home follow-ups. For the purpose of this 
analysis, loss to follow-up was deﬁ ned as missing three 
Overall 1997–2007 2008–11
Number of patients 72 061 38 546 33 515
Age, years 35 (28–42) 36 (29–43) 34 (27–42)
15–19 2028 (2·8%) 808 (2·1%) 1220 (3·6%)
20–24 7173 (10·0%) 2925 (7·6%) 4248 (12·7%)
25–29 12 146 (16·9%) 5909 (15·3%) 6237 (18·6%)
30–34 13 898 (19·3%) 7767 (20·1%) 6131 (18·3%)
35–39 12 939 (18·0%) 7537 (19·6%) 5402 (16·1%)
40–44 9559 (13·3%) 5788 (15·0%) 3771 (11·3%)
45–49 6763 (9·4%) 3920 (10·2%) 2843 (8·5%)
50–54 3892 (5·4%) 2072 (5·4%) 1820 (5·4%)
55–59 1908 (2·6%) 969 (2·5%) 939 (2·8%)
60–64 874 (1·2%) 429 (1·1%) 445 (1·3%)
≥65 881 (1·2%) 422 (1·1%) 459 (1·4%)
Sex
Men 26 055 (36·2%) 12 953 (33·6%) 13 102 (39·1%)
Women 46 006 (63·8%) 25 593 (66·4%) 20 413 (60·9%)
Marriage status
Married or living with partner 34 508 (47·9%) 16 547 (42·9%) 17 961 (53·6%)
Divorced or widowed 16 065 (22·3%) 9632 (25·0%) 6433 (19·2%)
Single 8021 (11·1%) 2787 (7·2%) 5234 (15·6%)
Other or unknown 13 467 (18·7%) 9580 (24·9%) 3887 (11·6%)
Mode of diagnosis
Voluntary counselling and testing 45 897 (63·7%) 25 508 (66·2%) 20 389 (60·8%)
Prevention of mother-to-child 
transmission
12 880 (17·9%) 6557 (17·0%) 6323 (18·9%)
Provider-initiated testing or 
other
13 284 (18·4%) 6481 (16·8%) 6803 (20·3%)
CD4 cell count at linkage 394 (210–636) 348 (183–606) 436 (253–663)
<50 cells per μL 3181 (4·4%) 1979 (5·1%) 1202 (3·6%)
50–99 cells per μL 3987 (5·5%) 2510 (6·5%) 1477 (4·4%)
100–199 cells per μL 9645 (13·4%) 6112 (15·9%) 3533 (10·5%)
200–349 cells per μL 15 170 (21·1%) 8493 (22·0%) 6677 (19·9%)
350–499 cells per μL 12 406 (17·2%) 6074 (15·8%) 6332 (18·9%)
≥500 cells per μL 27 005 (37·5%) 12 922 (33·5%) 14 083 (42·0%)
Unknown 667 (0·9%) 456 (1·2%) 211 (0·6%)
WHO disease stage
I 34 281 (47·6%) 14 798 (38·4%) 19 483 (58·1%)
II 18 113 (25·1%) 10 514 (27·3%) 7599 (22·7%)
III 15 525 (21·5%) 10 486 (27·2%) 5039 (15·0%)
IV 1721 (2·4%) 1068 (2·8%) 653 (1·9%)
Unknown 2421 (3·4%) 1680 (4·4%) 741 (2·2%)
Tuberculosis status at baseline
Negative 53 675 (74·5%) 26 239 (68·1%) 27 436 (81·9%)
Positive 12 265 (17·0%) 7077 (18·4%) 5188 (15·5%)
Unknown 6121 (8·5%) 5230 (13·6%) 891 (2·7%)
Cumulative loss to follow-up
Still in follow-up 65 027 (90·2%) 34 392 (89·2%) 30 635 (91·4%)
Lost to follow-up 7034 (9·8%) 4154 (10·8%) 2880 (8·6%)
(Table 1 continues on next page)
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consecutive months of health-care appointments and 
treatment pickups. Unsupervised treatment interruptions 
were not accounted for and were not classiﬁ ed as loss to 
follow-up at start of the treatment interruption. The 
demographic variables we used in this analysis included 
sex, age (categorised in 5-year categories for 15–64 years, 
and ≥65 years), and marital status. Clinical variables at 
enrolment included CD4 cell count status (<50, 50–99, 
100–199, 200–349, 350–499, and ≥500 cells per μL) and 
WHO disease stage (I, II, III, IV, and not reported), and 
route of diagnosis. We chose CD4 cell count categories 
based on levels known to be associated with increased 
risk of acquiring opportunistic infections, and levels used 
for antiretroviral therapy guidelines during the past 
decade. Route of diagnosis included voluntary counselling 
and testing, through prevention of mother-to-child 
transmission services, and through other means (such as 
provider-initiated testing and counselling, which began in 
2010, hospital admissions, and testing through 
comorbidities). Finally, we divided the study population 
into two periods, 1997–2007 and 2008–11, to account for 
changes in antiretroviral therapy guidelines that have 
taken place in Rwanda.
Statistical analysis
We assessed whether mortality diﬀ ered between the 
two periods speciﬁ ed. Mortality rates were expressed as 
number of deaths per 1000 person-years and stratiﬁ ed by 
age category, sex, and baseline CD4 cell count and WHO 
disease stage.
We constructed abridged life tables from age-speciﬁ c 
mortality rates using methods established by Chiang.8 
Life expectancy estimated from this type of life table is 
viewed as depicting the lifetime mortality experience of a 
single cohort of people who are subject to the mortality 
schedules on which the table is constructed. Therefore, 
life expectancy at an exact age is an indicator measuring 
the average number of additional years that will be lived 
by a person after that age, according to the age-speciﬁ c 
mortality rates for all deaths during the study period. 
Because a very large population and number of deaths 
are needed to overcome variations in mortality when 
constructing a complete life table by single years, we 
used abridged life tables by aggregated age groups, which 
describe the eﬀ ect of mortality on a sample of people if 
they were subjected to the mortality rates in the observed 
calendar periods.9 Complete details about these methods 
are provided in the appendix. Life expectancy was 
reported by age group and stratiﬁ ed by sex, CD4 cell 
count, and WHO disease stage at enrolment in care.
Central to the estimation of life expectancy through life 
tables is the estimation of mortality rates. Loss to follow-
up is known to account for a proportion of mortality 
among patients enrolled into care throughout sub-
Saharan Africa.10 At present, no studies tracing 
individuals lost to follow-up among the general HIV-
positive population of Rwanda have been reported. 
Approaches have been put forward to adjust for 
misclassiﬁ cation of mortality as loss to follow-up, but 
such approaches are based on estimates derived outside 
of Rwanda and exclusively among patients who had 
started antiretroviral therapy.11,12 By contrast, a substantial 
number of people lost to follow-up in our study were 
young and healthy. Just under half (46·2%) of all patients 
lost to follow-up could be classiﬁ ed as at high risk of 
mortality because they met at least one of the following 
conditions: CD4 count less than 200 cells per μL, positive 
tuberculosis screen, WHO disease stage of III or IV, age 
50 years or older, or an unreported tuberculosis screen or 
WHO disease stage. We estimated propensity scores for 
mortality using logistic regression with all available 
demographic and clinical variables. Individuals with the 
highest 46·2% propensities for mortality were recorded 
as deaths. In this manner, we avoided equally distributing 
the additional 46·2% of deaths through loss to follow-up 
among young and old or healthy and sick individuals. 
These mortality corrections for loss to follow-up were 
done separately for both time of enrolment and time of 
antiretroviral therapy initiation to study exit and used 
throughout the analyses. A sensitivity analysis with no 
adjustments for loss to follow-up is included in the 
appendix.
We also adjusted known underestimates of mortality in 
the oldest age group (age ≥65 years). Occasionally, the 
unbounded nature of the category led to selection bias. 
The distribution of age among people living with HIV/
AIDS and aged 65 years or older tends to be lower than 
the distribution of age among the general population 
within this age category, which in turn can lead to biased 
estimates of mortality. Within each stratiﬁ ed life 
expectancy analysis, we adjusted the mortality rate in the 
healthiest stratum with the lowest mortality rate to be 
equal to that of the general population for the 65 years 
and older age category and added the resulting constant 
to all other strata. No adjustments were made if the 
mortality rate for the 65 years and older age category was 
greater than in the general population.
Overall 1997–2007 2008–11
(Continued from previous page)
Death after enrolment
No 68 144 (94·6%) 35 918 (93·2%) 32 226 (96·2%)
Yes 3917 (5·4%) 2628 (6·8%) 1289 (3·8%)
Years of follow-up 2·6 (1·2–4·5) 4·4 (2·1–5·6) 1·8 (0·9–2·8)
Antiretroviral therapy initiated during follow-up
No 30 968 (43·0%) 14 092 (36·6%) 16 876 (50·4%)
Yes 41 093 (57·0%) 24 454 (63·4%) 16 639 (49·6%)
Years since starting antiretroviral 
therapy
2·6 (1·2–4·3) 3·9 (1·9–5·3) 1·6 (0·8–2·5)
Data are n (%) or median (IQR).
Table 1: Baseline characteristics of patients included in study, stratiﬁ ed by period of antiretroviral 
therapy coverage (1997–2007 and 2008–11)
See Online for appendix
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Potential years of life lost up to the age of 65 years, was 
used to assess the eﬀ ect of HIV on premature mortality. 
The potential years of life lost estimates the average years 
a person or group would have lived if they had not died 
prematurely. We calculated these values by multiplying 
the total number of deaths in each 5-year age group by 
the average number of years remaining in that age group, 
up to age 65 years. Potential years of life lost were 
expressed per 1000 people for ages 14–64 years.13 We 
stratiﬁ ed values by sex, WHO disease stage, and CD4 cell 
count at enrolment.
All signiﬁ cance tests were two sided, and p values of 
less than 0·05 were classiﬁ ed as statistically signiﬁ cant. 
All analyses were done with SAS software, version 9.3, 
R version 3.02, and Microsoft Excel 2013.
Role of the funding source
The funders had no role in the design and conduct of the 
study; in the collection, management, analysis, and 
interpretation of the data; or in the preparation, review, 
or approval of the report. The corresponding author had 
full access to all of the data in the study and takes 
responsibility for the integrity of the data, the accuracy of 
the data analysis, and the ﬁ nal decision to submit for 
publication.
Results
Our analyses were based on 72 061 patients from the 
IQ Charts database aged 15 years or older who enrolled 
in care in Rwanda between 1997 and 2011, contributing a 
total of 213 983 person-years of follow-up. Table 1 shows 
baseline characteristics for patients who enrolled in care 
overall and in two periods of antiretroviral therapy access 
in Rwanda. Median CD4 cell count at enrolment 
increased from 348 cells per μL (IQR 183–606) in the 
period 1997–2007 to 436 cells per μL (IQR 253–663) in the 
period 2008–11, resulting from a growth in capacity to 
deliver better care for people living with HIV. Similarly, 
median CD4 cell count at time of enrolment in care by 
year of enrolment showed an increase between the two 
periods (ﬁ gure 1). Cumulative loss to follow-up was low 
(7034 indi viduals, 9·8%).
For the overall cohort, the crude mortality rate was 
33·4 deaths per 1000 person-years (95% CI 32·7–34·2) 
and the potential years of life lost was 851·2 years per 
1000 people (95% CI 847·3–855·1). Mortality rates are 
presented in table 2. For both periods, we restricted 
mortality analyses to the ﬁ rst 3 years of follow-up to 
reduce survivor bias (risk of mortality decreases over 
time in care, so unequal follow-up would bias 
comparisons). The 3 year mortality rate was signiﬁ cantly 
decreased in the period of 2008–11 (37·4 deaths per 
1000 person-years, vs 41·1 deaths per 1000 person-years 
in 1997–2007, p<0·0001), after national guidelines for 
antiretroviral therapy in Rwanda raised CD4 cell count 
thresholds from 200 cells per μL. Women had a lower 
mortality rate than men, at 27·0 deaths per 1000 person-
years (95% CI 26·1–27·9) compared with 46·0 deaths per 
1000 person-years (95% CI 44·5–47·6), respectively. 
Similarly, potential years of life lost was less for women 
than men (2325·4 vs 2884·9 years per 1000 people). The 
mortality rate and potential years of life lost decreased 
substantially with increasing baseline CD4 cell count 
status. For patients with a baseline CD4 cell count less 
than 50 cells per μL, the mortality rate was 98·9 deaths 
per 1000 person-years (95% CI 92·5–105·6). For patients 
Number 
of deaths
Person-
years
Deaths per 1000 
person-years 
(95% CI)
Overall 7153 213 983·4 33·4 (32·7–34·2)
Period of antiretroviral therapy coverage*
1997–2007 3872 94 129·6 41·1 (39·8–42·5)
2008–11 2201 58 814·3 37·4 (35·9–39·0)
Sex
Men 3335 72 500·0 46·0 (44·5–47·6)
Women 3818 141 483·5 27·0 (26·1–27·9)
CD4 cell count at enrolment (cells per μL)
<50 889 8986·7 98·9 (92·5–105·6)
50–99 690 12 974·0 53·2 (49·3–57·3)
100–199 1204 32 660·6 36·9 (34·8–39·0)
200–349 1438 47 521·5 30·3 (28·7–31·9)
350–499 1063 35 193·2 30·2 (28·4–32·1)
≥500 1791 74 494·0 24·0 (22·9–25·2)
WHO Disease Stage
I 1380 95 758·9 14·4 (13·7–15·2)
II 1562 57 876·0 27·0 (25·7–28·4)
III 2683 51 987·1 51·6 (49·7–53·6)
IV 513 5088·6 100·8 (92·3–109·9)
*In view of the diﬀ erence in possible follow-up times, we restricted this variable to 
mortality within the ﬁ rst 36 months to reduce survival bias.
 Table 2: Crude mortality rates among HIV-positive patients
Figure 1: Median CD4 cell count at enrolment in care by year of enrolment
2004 contains all pre-200 3 participants because of a small number of enrollees.
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0
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with CD4 cell counts of 50–99 cells per μL, it was 
53·2 deaths per 1000 person-years (95% CI 49·3–57·3). 
Mortality consistently decreased through to patients with 
CD4 cell counts of 500 cells per μL or higher, with an 
estimated mortality rate of 24·0 deaths per 1000 person-
years (95% CI 22·9–25·2) in these patients (table 2). 
Similarly, the potential years of life lost among patients 
with a baseline CD4 cell count status less than 50 cells 
per μL was much higher (7015·9 per 1000 people) than in 
those with a baseline CD4 cell count of 500 cells per μL or 
higher (1693·6 per 1000 people).
Table 3 presents the results of the life expectancy 
analyses for patients with HIV enrolled in care. Life 
expectancy for the overall cohort was 25·6 years of 
additional life (95% CI 25·1–26·1) at 20 years of age and 
23·3 years of additional life (95% CI 22·9–23·7) at 
35 years of age. Life expectancy greatly decreased with 
decreasing CD4 cell count (ﬁ gure 2) at enrolment and 
with increasing WHO disease stage (ﬁ gure 3). A patient 
enrolled in care with WHO disease stage I at 20 years of 
age could expect an additional 42·5 years of life (95% CI 
41·5–43·5), by contrast with a 20-year-old patient enrolled 
at WHO disease stage IV who could expect 8·3 additional 
years (95% CI 6·6–10·0). We noted a similar trend 
among CD4 cell count strata at enrolment. 20-year-old 
patients enrolling with a CD4 cell count of 500 cells per 
μL or more could expect an additional 32·4 years of life 
(95% CI 31·5–33·3), compared with 8·1 additional years 
of life (95% CI 6·8–9·4) for 20-year-old patients with a 
CD4 cell count of less than 50 cells per μL at enrolment. 
Men had consistently shorter life expectancy than 
women. Life expectancy at 20 years of age for men was 
19·4 years of additional life (95% CI 18·4–20·4), 
compared with women at 20 years of age who had 
29·5 years of additional life (95% CI 6·8–9·4). Life 
expectancy at 20 years of age in the period of 1997–2007 
15–19 years 20–24 years 25–29 years 30–34 years 35–39 years 40–44 years 45–49 years 50–54 years 55–59 years 60–64 years ≥65 years*
General Rwandan life 
expectancy (WHO, 
2002–14)14
44–55 40–51 36–46 32–42 29–38 27–34 24–30 21–26 18–22 15–18 NA
Overall 26·7
(25·9–27·5)
25·6
(25·1–26·1)
25·5
(25·1–25·9)
24·5
(24·1–24·9)
23·3
(22·9–23·7)
21·7
(21·3–22·1)
20·0
(19·6–20·4)
18·1
(17·6–18·6)
16·1
(15·6–16·6)
14·2
(13·8–14·7)
12·5
Men 21·9
(20·5–23·3)
19·4
(18·4–20·4)
19·9
(19·2–20·6)
19·9
(19·3–20·5)
19·8
(19·3–20·3)
18·6
(18·1–19·1)
17·6
(17·1–18·1)
16·1
(15·5–16·7)
14·6
(14·0–15·2)
13·0
(12·4–13·6)
11·5
Women 29·8
(28·6–31·0)
29·5
(28·8–30·2)
29·6
(29·0–30·2)
28·6
(28·0–29·2)
27·2
(26·6–27·8)
25·5
(24·8–26·2)
23·6
(22·9–24·3)
21·3
(20·5–22·1)
18·8
(18·0–19·6)
16·5
(15·8–17·2)
14·8
Period of antiretroviral therapy coverage
1997–2007 21·3
(19·9–22·7)
20·4
(19·5–21·3)
20·8
(20·2–21·4)
19·9
(19·3–20·5)
19·0
(18·4–19·6)
17·6
(16·9–18·3)
16·4
(15·7–17·1)
14·6
(13·8–15·4)
12·5
(11·6–13·4)
10·3
(9·5–11·1)
8·7
2008–11 27·2
(26·0–28·4)
25·6
(24·8–26·4)
24·2
(23·5–24·9)
22·9
(22·2–23·6)
21·5
(20·7–22·3)
19·8
(19·0–20·6)
18·7
(17·8–19·6)
17·3
(16·3–18·3)
16·2
(15·1–17·3)
15·0
(13·9–16·1)
15·4
CD4 at enrolment
<50 cells per μL 10·4
(8·5–12·3)
8·1
(6·8–9·4)
9·2
(8·3–10·1)
9·5
(8·7–10·3)
10·6
(9·8–11·4)
10·6
(9·8–11·4)
10·5
(9·6–11·4)
9·1
(8·1–10·1)
7·7
(6·6–8·8)
5·5
(4·3–6·7)
5·0
50–99 cells per μL 15·3
(12·1–18·5)
14·5
(12·2–16·8)
17·9
(16·5–19·3)
17·6
(16·5–18·7)
17·6
(16·5–18·7)
16·2
(15·0–17·4)
14·8
(13·5–16·1)
14·0
(12·6–15·4)
11·9
(10·3–13·5)
10·3
(8·6–12·0)
10·5
100–199 cells per μL 22·8
(20·4–25·2)
20·5
(18·8–22·2)
22·2
(21·1–23·3)
22·8
(21·9–23·7)
22·0
(21·2–22·8)
20·6
(19·7–21·5)
18·4
(17·5–19·3)
16·3
(15·3–17·3)
13·9
(12·9–14·9)
11·6
(10·7–12·5)
9·8
200–349 cells per μL 27·7
(25·6–29·8)
26·7
(25·4–28·0)
26·9
(26·0–27·8)
25·9
(25·1–26·7)
24·7
(23·9–25·5)
22·8
(21·9–23·7)
20·9
(20·0–21·8)
18·5
(17·6–19·4)
16·3
(15·4–17·2)
14·4
(13·6–15·2)
12·0
350–499 cells per μL 28·3
(25·9–30·7)
27·6
(26·2–29·0)
28·1
(26·9–28·5)
27·3
(26·1–28·5)
25·5
(24·3–26·7)
23·7
(22·4–25·0)
22·3
(20·9–23·7)
20·4
(18·9–21·9)
18·7
(17·2–20·2)
17·8
(16·4–19·2)
16·7
≥500 cells per μL 33·1
(31·6–34·6)
32·4
(31·5–33·3)
31·5
(30·7–32·3)
30·1
(29·3–30·9)
28·2
(27·4–29·0)
25·9
(25·1–26·7)
23·9
(23·0–24·8)
21·6
(20·7–22·5)
19·3
(18·4–20·2)
16·9
(15·3–16·9)
14·5
WHO stage at enrolment
I 45·5
(44·1–46·9)
42·5
(41·5–43·5)
40·7
(39·8–41·6)
38·3
(37·4–39·2)
35·7
(24·8–36·6)
32·7
(37·8–33·6)
29·9
(29·0–30·8)
27·3
(26·4–28·2)
24·3
(23·4–22·7)
22·0
(21·3–22·7)
19·0
II 32·9
(31·1–34·7)
30·6
(29·4–31·8)
29·9
(29·0–30·8)
28·5
(27·6–29·4)
27·0
(26·1–27·9)
25·0
(24·5–26·5)
23·2
(22·2–24·2)
21·0
(19·9–22·1)
19·5
(18·4–20·6)
17·6
(16·5–18·7)
16·8
III 16·8
(15·4–18·2)
15·5
(14·5–16·5)
17·3
(16·6–18·0)
18·3
(17·7–18·9)
18·2
(17·6–18·8)
17·3
(16·7–18·)
16·1
(15·5–16·7)
14·5
(13·8–15·2)
12·3
(11·6–13·0)
10·5
(9·8–11·2)
8·9
IV 9·9
(7·6–12·2)
8·3
(6·6–10·0)
9·9
(8·7–11·1)
9·6
(8·6–10·6)
9·6
(8·6–10·6)
10·0
(8·9–11·1)
10·9
(9·6–12·2)
9·7
(8·2–11·2)
8·6
(6·9–10·3)
7·6
(6·0–9·2)
5·7
Table shows additional years of life (95% CI). Life expectancy was deﬁ ned as the average number of additional years that will be lived by a person after that age. General Rwandan life expectancy is presented as 
the range of the time period 2002–14, covering most our study period. NA=not applicable. *95% CIs not available for age ≥65 years because it is not a closed interval.
Table 3: Life expectancy among HIV-positive patients enrolled in care, by age category
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was 20·4 additional years (95% CI 19·5–21·3) and in the 
period of 2008–11 was 25·6 additional years (95% CI 
24·8–26·4). The life expectancy among individuals 
enrolling in care with WHO disease stage I had estimated 
projections that fell within the range of life expectancies 
for the general Rwandan population during the study 
period, across all age categories.
Table 4 presents the results of life expectancy following 
patients starting from antiretroviral therapy initiation. Life 
expectancy for the overall cohort was 29·9 years of 
additional life (95% CI 29·1–30·7) at 20 years of age and 
25·6 years of additional life (95% CI 25·0–26·2) at 35 years 
of age. The diﬀ erence between life expectancy for 
individuals in enrolled in HIV care not yet receiving 
antiretroviral therapy compared with that of individuals 
receiving antiretroviral therapy was greatest among 
younger people (an additional 4·3 years among 20-year-
olds) and decreased to 1·3 years among those aged 65 years 
or older. We noted similar patterns in this subset for sex, 
WHO disease stage, antiretroviral therapy coverage period, 
and the lower CD4 categories.
The additional life expectancy estimated in the analysis 
restricted to those on antiretroviral therapy was 
not shared equally among the CD4 strata. Among 
20–24-year -olds, the jump was 4·0 years in the lowest 
CD4 category and 12·7 years in the 350–499 cells per μL 
group. Diﬀ erences between the 350–499 cells per μL 
group and the 500 cells per μL or higher group were not 
statistically signiﬁ cant, as shown by the overlapping 95% 
CIs. The life expectancy estimates were slightly lower in 
the 500 cells per μL or higher group, due to a higher 
propensity of linking and initiation of antiretroviral 
therapy at higher CD4 for other clinical reasons, such as 
opportunistic infections.
The appendix shows the estimated life expectancies 
across CD4 categories when no adjustments were made 
for mortality among individuals lost to follow-up. By 
comparison with the main analysis, we estimated the life 
expectancies to be much higher in the unadjusted 
analysis. Moreover, life expectancies among the higher 
CD4 categories in the unadjusted sensitivity analysis 
seemed to be almost entirely accounted for by age, 
whereas life expectancy among younger individuals 
seemed to be ﬂ atter in the age categories of 15–35 years 
when accounting for loss to follow-up. This diﬀ erence 
suggests that many deaths among younger patients 
could be undetected because of loss to follow-up.
Discussion
Our study supports life expectancy gains for enrolment 
of patients into HIV care at any CD4 cell count, as shown 
by improved life expectancy between the two periods of 
lower and higher coverage of antiretroviral therapy at 
both time of enrolment and initiation of antiretroviral 
therapy. We noted that life expectancy varied by sex, with 
women having greater gains than men, and that access to 
antiretroviral therapy greatly improved life expectancy, 
particularly among patients with high baseline CD4 
status. To our knowledge, this study is the ﬁ rst to assess 
life expectancy among patients enrolling in care and 
those initiating antiretroviral therapy in two distinct 
periods, deﬁ ned by antiretroviral therapy coverage and 
CD4 cell count at enrolment in care and antiretroviral 
therapy initiation (panel).
In 2014, the WHO Global Health Observatory 
Repository estimated life expectancy in Rwanda at age 
20 years to be an additional 45 years of life, a 35% gain in 
just 10 years.14 Although Rwanda had almost no provision 
Figure 2: Life expectancy (additional years of life) among HIV-positive individuals overall according to CD4 
cell count at time of enrolment
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for antiretroviral therapy before the ﬁ nancial assistance 
provided by the US President’s Emergency Plan for AIDS 
Relief and the Global Fund to Fight AIDS, Tuberculosis 
and Malaria, the government made a speciﬁ c target of 
antiretroviral therapy initiation in rural settings and 
among individuals infected with HIV during the 
Rwandan genocide of 1994.4 This early response is, partly, 
responsible for the impressive coverage of antiretroviral 
therapy across Rwanda, and ability of the government to 
reach targets for universal access to antiretroviral therapy 
(deﬁ ned as >80% coverage at a CD4 cell count of >200 cells 
per μL before 2009 and >350 cells per μL afterwards). 
Now, with assistance from the US President’s Emergency 
Plan for AIDS Relief and the Global Fund to Fight AIDS, 
Tuberculosis and Malaria, as of July, 2014, the Rwanda 
Ministry of Health now advises the initiation of 
antiretroviral therapy at a CD4 threshold of 500 cells per 
μL or immediate therapy to speciﬁ c populations including 
men who have sex with men, female sex workers, and 
other high-risk populations, with the objective to reduce 
mortality, reduce HIV transmission, and increase 
coverage of antiretroviral therapy.7
There are several strengths and limitations to this 
study. Strengths include the large sample size (roughly 
21% of all Rwandans infected by HIV) that was nationally 
representative and included a diverse population of 
patients with varying levels of health. This aspect 
provided precise estimates throughout the analyses, and 
allowed for granular categorisation of age. We also had a 
very large number of early enrollers (enrolling at CD4 
cell counts >350 cells per μL) that allowed us to project 
the life expectancy gains for people enrolling in care 
15–19 years 20–24 years 25–29 years 30–34 years 35–39 years 40–44 years 45–49 years 50–54 years 55–59 years 60–64 years ≥65 years*
General Rwandan life 
expectancy (WHO, 
2002–14)14
44–55 40–51 36–46 32–42 29–38 27–34 24–30 21–26 18–22 15–18 NA
Overall 31·9
(30·6–33·2)
29·9
(29·1–30·7)
28·9
(28·3–29·5)
27·4
(26·8–28·0)
25·6
(25·0–26·2)
23·4
(22·8–24·0)
21·3
(20·7–21·9)
19·3
(18·6–20·0)
17·0
(16·3–17·7)
14·9
(14·2–15·6)
13·8
Men 24·1
(21·8–26·4)
22·2
(20·2–24·2)
23·7
(22·6–24·8)
23·3
(22·4–24·2)
22·8
(22·0–23·6)
21·2
(20·4–22·0)
19·7
(18·9–20·5)
18·1
(17·2–19·0)
16·2
(15·2· 17·2)
14·7
(13·7–15·7)
14·2
Women 35·7
(34·1–37·3)
33·2
(32·2–34·2)
31·8
(31·0–32·6)
30·1
(29·3–30·9)
28·0
(27·2–28·8
25·6
(24·7–26·5)
23·2
(22·3–24·1)
20·5
(19·6–21·4)
17·8
(16·8–18·8)
15·1
(14·2–16·0)
13·2
Period of antiretroviral 
therapy coverage
1997–2007 21·7
(19·3–24·1)
21·1
(19·5–22·7)
21·4
(20·4–22·4)
20·2
(19·4–21·0)
18·9
(18·1–19·7)
17·3
(16·4–18·2)
15·4
(14·5–16·3)
13·7
(12·7–14·7)
11·2
(10·1–12·3)
8·6
(7·5–9·7)
7·2
2008–11 31·6
(29·9–33·3)
28·9
(27·8–30·0)
27·2
(26·2–28·2)
25·7
(24·7–26·7)
23·8
(22·8–24·8)
21·5
(20·5–22·5)
19·7
(18·6–20·8)
17·8
(16·6–19·0)
16·4
(15·1–17·7)
15·2
(13·9–16·5)
15·4
CD4 at enrolment
<50 cells per μL 13·6
(11·0–16·2)
12·1
(10·3–13·9)
12·2
(10·9–13·5)
12·7
(11·6–13·8)
13·5
(12·5–14·5)
13·1
(12·0–14·2)
12·7
(11·5–13·9)
10·9
(9·6–12·2)
8·9
(7·4–10·4)
7·2
(5·6–8·8)
6·9
50–99 cells per μL 22·4
(18·3–26·5)
21·2
(18·5–23·9)
21·6
(20·0–23·2)
20·4
(19·1–21·7)
20·0
(18·7–21·3)
18·0
(16·7–19·3)
16·2
(14·8–17·6)
15·2
(13·6–16·8)
12·8
(11·1–14·5)
10·3
(8·6–12·0)
10·4
100–199 cells per μL 30·1
(27·3–32·9)
27·3
(25·2–29·4)
27·7
(26·4–29·0)
27·0
(25·9–28·1)
25·4
(24·4–26·4)
23·3
(22·3–24·3)
20·8
(19·7–21·9)
18·4
(17·3–19·5)
15·7
(14·5–16·9)
13·4
(12·3–14·5)
11·9
200–349 cells per μL 38·4
(36·0–40·8)
36·1
(34·5–37·7)
34·7
(33·5–35·9)
32·6
(31·5–33·7)
29·8
(28·7–30·9)
27·2
(26·0–28·4)
24·6
(23·4–25·8)
22·3
(21·1–23·5)
20·0
(18·8–21·2)
17·7
(16·6–18·8)
15·8
350–499 cells per μL 43·3
(39·7–46·9)
40·3
(37·9–42·7)
38·0
(36·0–40·0)
35·1
(33·2–37·0)
31·7
(29·8–33·6)
28·3
(26·3–30·3)
25·4
(23·4–27·4)
22·6
(20·5–24·7)
20·0
(18·0–22·0)
17·5
(15·7–19·3)
15·4
≥500 cells per μL 39·8
(35·5–44·1)
38·0
(35·3–40·7)
35·2
(32·7–37·7)
33·2
(30·7–35·7)
30·5
(28·0–33·0)
27·6
(25·0–30·2)
24·9
(22·3–27·5)
22·1
(19·4–24·8)
19·6
(16·9–22·3)
17·2
(14·8–19·7)
15·3
WHO stage at 
enrolment
I 50·0
(48·2–51·8)
45·5
(44·0–47·0)
42·5
(41·2–43·8)
39·1
(37·8–40·4)
35·4
(34·2–36·6)
31·9
(30·6–33·2)
28·3
(27·0–29·6)
25·0
(23·7–26·3)
21·4
(20·2–22·6)
18·2
(17·1–19·3)
15·4
II 38·0
(35·7–40·3)
34·9
(33·3–36·5)
32·9
(31·8–34·0)
29·9
(28·8–31·0)
27·3
(26·3–28·3)
24·3
(23·3–25·3)
21·1
(20·0–22·2)
18·5
(17·4–19·6)
15·9
(14·8–17·0)
13·1
(12·0–14·2)
11·4
III 21·1
(19·1–23·1)
19·7
(18·2–21·2)
20·6
(19·7–21·5)
21·2
(20·5–21·9)
20·5
(19·8–21·2)
18·7
(18·0–19·4)
16·9
(16·2–17·6)
14·8
(14·1–15·5)
12·2
(11·5–12·9)
9·8
(9·1–10·5)
7·6
IV 12·2
(9·4–15·0)
10·2
(8·0–12·4)
10·8
(9·3–12·3)
11·1
(9·8–12·4)
10·8
(9·6–12·0)
11·3
(9·9–12·7)
11·8
(10·2–13·4)
10·9
(9·0–12·8)
10·2
(7·9–12·5)
9·2
(7·0–11·4)
8·2
Table shows additional years of life (95% CI). Life expectancy was deﬁ ned as the average number of additional years that will be lived by a person after that age. General Rwandan life expectancy is presented as 
the range of the time period 2002–14, covering most our study period. NA=not applicable. *95% CIs not available for age ≥65 years because it is not a closed interval.
Table 4: Life expectancy among HIV-positive patients enrolled in HIV care after initiating antiretroviral therapy, by age category
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early. Moreover, our study assessed both time in HIV 
care and time on antiretroviral therapy, recognising the 
importance of the pre-antiretroviral therapy period in 
which loss to follow-up is increased. Nonetheless, loss to 
follow-up was low in this study, consistent with other 
studies that have shown Rwanda to have among the 
highest retention rates in sub-Saharan Africa,18 and 
serving to reduce the potential for misclassiﬁ cation bias 
in this study. Finally, through adjustments to mortality 
for loss to follow-up, including loss to follow-up in the 
pre-antiretroviral therapy period, our study underscores 
the additional strain on life expectancy experienced by 
younger HIV-positive patients.
Limitations include ﬁ rst the absence of important 
baseline variables, notably viral load, which serves as a 
marker of treatment adherence but which remains limited 
in Rwanda to HIV-positive patients on antiretroviral 
therapy. Second, we adjusted for mortality among loss to 
follow-up through propensity adjustments using a 
conservative proportion of mortality (ie, a proportion that 
was probably too high), which could lead to underestimation 
of life expectancy. By contrast with a recent study from 
South Africa,15 we could not link our HIV cohort data with 
the national death register in Rwanda. Third, we only 
considered one clinical marker at a time, which would not 
include individuals initiating antiretroviral therapy with 
high CD4 cell counts due to opportunistic infections and 
patients not initiating antiretroviral therapy despite low 
CD4 cell counts. Finally, missing values for WHO disease 
stage (2421 individuals, 3·4%) might have aﬀ ected the 
mortality rates and life expectancy for both these variables.
Within the international community for AIDS research 
and implementation there is substantial debate about the 
value of CD4 cell count as a threshold for initiation of 
antiretroviral therapy.19–21 In our study we noted that 
higher CD4 status at initiation of therapy increased life 
expectancy. Other study ﬁ ndings have shown that early 
initiation of antiretroviral therapy reduces clinical events 
and infectiousness, the likelihood transmission of 
disease to a sexual partner, and the acquisition of 
tuberculosis,19,22–24 raising the question of whether CD4 
thresholds for initiation have any value to the health of 
the population. Understanding of baseline disease risk is 
valuable to physicians, but in view of the substantial 
challenges involved with retention of patients in pre-
antiretroviral therapy, there is growing support for a 
simpliﬁ ed system in which patients are placed on 
treatment immediately after enrolment in care.25
In summary, our study ﬁ ndings add to the growing 
body of evidence that early enrolment and antiretroviral 
therapy have several beneﬁ ts that extend well beyond 
immediate reductions in mortality. These ﬁ ndings 
strongly support the Rwandan Government’s policy 
change to provide antiretroviral therapy at an increased 
CD4 threshold and their continued eﬀ orts to improve 
retention and testing.
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